Here is Why CRISPR Therapeutics (CRSP) Appears so Good

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the 10 most shorted biotech stocks to buy according to hedge funds.

On February 17, Morgan Stanley increased its price target on CRISPR Therapeutics AG (NASDAQ:CRSP) from $32 to $33, while maintaining an Underweight rating on the stock.

The firm updated its estimates for CRISPR Therapeutics AG (NASDAQ:CRSP) and evaluated additional pipeline advancements after its partner Vertex Pharmaceuticals (VRTX) disclosed fourth-quarter sales data of Casgevy.

On February 13, Needham increased the firm’s price target on CRISPR Therapeutics AG (NASDAQ:CRSP) from $80 to $82. The firm maintained its Buy rating on the shares that offer more than 45% upside potential after the revision.

Following the company’s Q4 results, the firm noted that Casgevy generated $116 million in sales in 2025, surpassing Vertex’s previously stated target of approximately $100 million. The stronger-than-expected sales performance highlights early commercial traction for the therapy, supporting a positive outlook for the company.

CRISPR Therapeutics AG (NASDAQ:CRSP) is a gene editing company developing potentially curative medicines for serious diseases. Their groundbreaking therapy CASGEVY targets sickle cell disease and blood disorders, while their broader pipeline tackles cancer, autoimmune conditions, and diabetes. This has positioned them as a leader in the future of genetic medicine.

While we acknowledge the potential of CRSP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 12 Oversold Financial Stocks to Invest in According to Hedge Funds.

Disclosure: None. Follow Insider Monkey on Google News.